Novartis International AG http://www.novartis.com Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes 2010-05-22T16:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1418121.shtml NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance 2010-03-14T13:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1393715.shtml Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer 2010-01-20T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1375090.shtml Novartis completes shipment of US supply of Fluvirin® seasonal influenza vaccine 2009-10-06T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1345850.shtml About seasonal influenza Novartis begins shipment of Fluvirin® seasonal influenza vaccine for the U.S. market ahead of schedule 2009-08-05T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1332676.shtml Basel, August 5, 2009 - Novartis Vaccines has started shipping seasonal influenza vaccine to U.S. healthcare facilities for the 2009-2010 season. The company delivered Fluvirin® influenza virus vaccine, which has been approved by the U.S. Food and Drug Administration (FDA), to the U.S. weeks ahead of schedule in anticipation of the increased demand for seasonal influenza vaccine created by the current global (A) H1N1 influenza pandemic. Japanese Ministry of Health approves Rasilez®, a first-in-class direct renin inhibitor (DRI), for the treatment of high blood pressure 2009-07-08T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1327640.shtml Basel, July 8, 2009 - Rasilez® (aliskiren), the first new type of high blood pressure medicine in more than a decade, has been approved for use in Japan. Rasilez directly inhibits renin[9], an enzyme that triggers a process leading to high blood pressure and organ damage. The Ministry of Health, Labour and Welfare (MHLW) in Japan approved Rasilez for the treatment of high blood pressure alone or in combination with other high blood pressure medicines. Rasilez®, first-in-class direct renin inhibitor, provides greater reduction in high blood pressure than ACE inhibitor ramipril in patients 65 and older 2008-11-11T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1268561.shtml Basel, November 11, 2008 - New clinical data presented today show first-in-class direct renin inhibitor Rasilez® [*] (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in patients with high blood pressure aged 65 and over, compared to the angiotensin-converting enzyme (ACE) inhibitor ramipril[1]. Data show Galvus® better tolerated by patients with type 2 diabetes, with no weight gain, a favorable cardiovascular profile and equal efficacy compared to widely-used TZDs 2008-09-09T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1249901.shtml Basel, September 9, 2008 - New data show Galvus® (vildagliptin), an oral treatment for type 2 diabetes, is better tolerated and as effective as commonly prescribed anti-diabetic oral medicines, called thiazolidinediones (TZDs), when added to metformin[1]. Patients treated with Galvus did not gain weight, a common side effect of other type 2 diabetes medicines, regardless of their race, body mass index or age[1]. Rasilez® , first-in-class direct renin inhibitor, lowers high blood pressure more effectively than diuretic in obese patients 2008-09-03T12:35:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1248468.shtml Basel, September 3, 2008 - New clinical data analysis confirms that the first-in-class direct renin inhibitor Rasilez® (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in obese patients with high blood pressure compared to the diuretic hydrochlorothiazide (HCT) alone[1]. Novartis begins shipment to US of Fluvirin® Influenza Virus Vaccine with three new strains for the 2008-2009 influenza season 2008-08-07T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1241557.shtml Basel, August 7, 2008 - Novartis announced today that it started shipments of its Fluvirin® Influenza Virus Vaccine to US health care facilities and practitioners for the 2008/2009 influenza season. Gestützt auf eine verstärkte Innovationsdynamik erzielt Novartis im zweiten Quartal eine starke finanzielle Performance 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1431807.shtml Das Gesundheitsportfolio von Novartis erzielt im ersten Quartal 2010 starke Zuwächse - mit Fortschritten bei Innovation, Wachstum und Produktivität 2010-04-20T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1405500.shtml Novartis erzielt 2009 Rekordergebnisse - Neu eingeführte Produkte erweisen sich als Wachstumstreiber 2010-01-26T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1377020.shtml Novartis verzeichnet in den ersten neun Monaten 2009 eine kräftige Dynamik der neuen Produkte und erzielt eine starke operative Performance 2009-10-22T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1349244.shtml Neun Monate bis 30. September Novartis erzielt im ersten Halbjahr 2009 eine starke operative Performance - dank der anhaltenden Innovationskraft der Division Pharmaceuticals 2009-07-16T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1329092.shtml Erstes Halbjahr Novartis verzeichnet im ersten Quartal 2009 eine starke Expansion der Division Pharmaceuticals und setzt die Verjüngung des Produktportfolios fort 2009-04-23T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1329173.shtml Novartis erzielt in den ersten neun Monaten 2008 eine anhaltend starke Performance, getragen vom beschleunigten Wachstum der Division Pharmaceuticals 2008-10-20T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2008/1260875.shtml Neun Monate bis 30. September